Jinwon Life Sciences Registers U.S. Patent for GLS-1200 Nasal Spray Treatment
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 6th that it has received a patent registration from the United States Patent and Trademark Office for the core technology of GLS-1200, a nasal spray treatment for preventing infection of the novel coronavirus disease (COVID-19) and a treatment for sinusitis.
The patent, titled "Diagnosis and Treatment of Respiratory Diseases," includes substances that stimulate bitter taste receptors in the upper respiratory tract to induce innate immunity that treats bacterial infections, as well as all developments of pharmaceuticals using these substances.
A company official stated, "A second patent titled 'Utilization of Quinine to Induce Innate Immunity' has also been filed using the registered patent technology. This patent application expands the core technology to antiviral indications such as the COVID-19 virus."
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Park Younggeun, CEO of GeneOne Life Science, said, "Since the registered patent is a platform technology, it is highly valuable. Our company is continuously collaborating with university research institutions such as the University of Pennsylvania, Philadelphia Veterans Medical Center, and Monell Chemical Senses Center to further expand indications using this technology."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
